LONDON, UK: AstraZeneca today completed the acquisition of Alexion Pharmaceuticals Inc. The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca. AstraZeneca now has an enhanced scientific presence in immunology and, through Alexion’s innovative complement-biology platform and robust pipeline, will continue to…
Tag: Alexion Pharmaceuticals
AstraZeneca signs definitive agreement to acquire Alexion Pharmaceuticals
CAMBRIDGE: AstraZeneca and Alexion Pharmaceuticals Inc. have entered into a definitive agreement for AstraZeneca to acquire Alexion, a news release said. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each…